B7-H3 Antibody
- Known as:
- B7-H3 Antibody
- Catalog number:
- amm00012
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- B7-H3 Antibody
Related genes to: B7-H3 Antibody
- Gene:
- CD276 NIH gene
- Name:
- CD276 molecule
- Previous symbol:
- -
- Synonyms:
- B7-H3, B7H3, B7RP-2
- Chromosome:
- 15q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-03-04
- Date modifiied:
- 2016-10-05
Related products to: B7-H3 Antibody
Related articles to: B7-H3 Antibody
- : B7-H3, a type I transmembrane glycoprotein belonging to the B7 superfamily, is an attractive target for antitumor therapies. B7-H3 demonstrates aberrant overexpression in various types of solid tumors while showing limited and low expression in normal human organs. Various types of treatment targeting B7-H3 have been reported. Among these treatments, antibody-drug conjugates (ADCs) have shown potent activity, and several clinical trials, including DS7300a and MGC018, are currently ongoing. : Here, we constructed CD276-8 ADC, composed of the anti-B7-H3 antibody CD276-8 with moderate affinity, an enzymatically cleavable tetra-peptide-based linker and DXd. Characteristics, including in vitro binding affinity and internalization activity, were assessed by bio-layer interferometry (BLI), flow cytometry and high content analysis (HCA). The cytotoxicity of CD276-8 ADC was evaluated in cell lines expressing B7-H3. Pharmacokinetic profiles and antitumor activity were evaluated in mouse models in vivo. Finally, the developability of CD276-8 ADC was assessed with plasma stability, accelerated stability and freeze-thaw studies using LC-MS and HPLC. : Characterization in vitro demonstrated the moderate affinity and acceptable internalization activity of CD276-8 ADC. In addition, CD276-8 ADC exhibited potent antitumor activities in B7-H3-positive cell line-derived xenograft (CDX) models with acceptable pharmacokinetic profiles, although it showed less potent cytotoxicity in various cell lines in vitro, indicating acceptable developability. : We developed CD276-8 ADC, a B7-H3-targeting ADC with moderate affinity, which delivers the TOP1 inhibitor DXd. This design combined moderate affinity and acceptable pharmacokinetics, resulting in potent antitumor efficacy in vivo. Our study suggests that affinity optimization could be a useful consideration for enhancing ADC efficacy, positioning CD276-8 ADC as a promising therapeutic for B7-H3-expressing solid tumors. - Source: PubMed
Publication date: 2026/04/08
Zhang ZiyuZong HuifangLi ZhenWang ShushengXiao XiaodongXie YueqingZhu Jianwei - Mycosis fungoides (MF) is the predominant subtype of cutaneous T-cell lymphoma, whereas large plaque parapsoriasis (LPP) closely resembles early-stage MF, making differential diagnosis challenging. Immune markers, such as CD47, CD163, and B7-H3, play crucial roles in tumor immune evasion and macrophage polarization. However, their expression profiles and potential diagnostic or prognostic implications in early-stage MF and LPP remain poorly defined. Therefore, this study aimed to evaluate the expression of CD47, CD163, and B7-H3 in early-stage MF and LPP and analyze their associations with clinicopathological characteristics and patient outcomes. This retrospective study evaluated the immunohistochemical expression of CD47, CD163, and B7-H3 in 46 patients with early-stage mycosis fungoides (MF) and 46 patients with large plaque parapsoriasis (LPP). Expression levels were assessed using an immunoreactivity scoring system and analyzed for their associations with clinical parameters and disease-free survival (DFS). The study included patients diagnosed and followed at Sivas Cumhuriyet University between 1 March 2015 and 31 March 2025. : High CD47 expression was detected in 72.7% of MF patients, high B7-H3 expression in 45.7%, and high CD163 expression in 46.7% compared with LPP patients ( < 0.001). These markers showed positive correlations, and elevated expression, especially of B7-H3 and CD163, was associated with shorter disease-free survival in univariate analysis. : The higher expression of CD47, CD163, and B7-H3 in early-stage MF compared with LPP suggests that these markers may contribute to the differential diagnosis and could represent potential therapeutic targets; however, their independent prognostic value requires confirmation in larger studies. - Source: PubMed
Publication date: 2026/04/02
Yasak Guner RukiyeYüceer Ramazan OguzUnsal Ahmet Turan - B7-H3 is a cell surface protein overexpressed in many solid tumors and an attractive target for chimeric antigen receptor (CAR) T cell therapy. The most clinically advanced B7-H3 CARs derive from murine monoclonal antibodies (mAbs) 376.96 and MGA271 and are now in phase 1/2 trials. However, non-human mAb sequences can provoke immune responses, leading to CAR T cell rejection and therapeutic failure. Although single-chain variable fragment (scFv) humanization reduces this risk, residual foreign residues within variable domains remain. To overcome this limitation, here we use in vitro phage display to generate fully human B7-H3-specific scFvs for CAR design. In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 are well tolerated and demonstrate superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induces complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors. - Source: PubMed
Publication date: 2026/04/29
Bajgain PradipFeng YangPuebla MarielaTian MeijieHsu Kuo-ShengLee JaewonYu GuoJunYang LipingSeaman StevenHilton Mary BethMorris KarenBorchin NizaTran Jennifer DMetcalfe Riley DLi DanHo MitchellCronk James CKhan JavedNellan AnandaniKaplan Rosandra NSt Croix Brad - Antibody-drug conjugate (ADC) represents an effective therapeutic strategy for cancer, leveraging a cancer-targeting monoclonal antibody (mAb) linked to a potent payload. In this study, we report novel dual-payload ADCs (DualADC), which harness one antibody to simultaneously deliver chemotherapy and immunotherapy for aggressive triple-negative breast cancer (TNBC). Specifically, we developed two-site, that is, cysteine and lysine, co-conjugation technologies to link a chemotherapeutic agent for direct tumor cell killing and a Toll-like receptor dual agonist for tumoral immunity enhancement to our humanized anti-CD276 (B7-H3) mAb. Our antibody binds to TNBC with high affinity and selectivity while exhibiting minimal off-target effects in normal human tissues. Three DualADCs were fully characterized by validating the conjugations and quantifying the drug-to-antibody ratios and drug-to-drug ratio using several analytic tools. In vitro evaluations revealed a high cancer cell binding rate via flow cytometry, efficient drug internalization with confocal microscopy, and high anticancer cytotoxicity in three TNBC cell lines. In vivo investigations in two TNBC xenograft mouse models demonstrated that DualADC carrying deruxtecan and imidazoquinoline has the best antitumor efficacy, that is, favorable biodistribution in TNBC, high tumor burden reduction, low systemic toxicity, and upregulation of immune pathways. Collectively, this study establishes advanced dual-payload antibody-drug conjugation technologies and identifies a good DualADC candidate for cancer therapy. - Source: PubMed
Zhou ZhuoxinBallard DavisZhang JiashuaiDu ZhantaoWatcharadulyarat NatsornVaradkar TanviChowdhury SrijitaKambam Sathvik RHu PhoebeKhanal SelenaZhou LufangLiu Xiaoguang - B7-H3 (CD276) represents a promising therapeutic target tested in high-risk localized and treatment-refractory metastatic prostate cancer (PC). To guide therapeutic development and treatment strategies, we examined prostate tumors and evaluated expression, molecular features, and overall survival (OS), accounting for tissue site, hormone-sensitivity status, and race. - Source: PubMed
Publication date: 2026/04/21
Makovec AllisonGustafson Ava PGandhi NishantRampalli SwatiArafa Ali TElliott AndrewSmith NormFelices MartinKennedy Philippa RShenderov EugenePatnaik AkashNarayan VivekHeath Elisabeth IZorko Nicholas AShi XiaoleiAntonarakis Emmanuel SMcKay Rana RHwang Justin